Caps amount payable for 30 day supply of equipment/supplies for insulin administration/glucose monitoring at $25 or equipment designed to last more than 30 days with no deductible commencing January 1, 2026.
S0196 amends Rhode Island’s insurance laws to require most individual and group health plans, including accident and sickness policies, nonprofit hospital service corporation plans, nonprofit medical service corporation plans, and health maintenance organization plans, to cover diabetes treatment supplies and equipment when medically appropriate and prescribed by a physician. The covered items include blood glucose monitors, test strips, insulin, syringes, insulin pumps and related appurtenances, insulin infusion devices, oral agents for blood sugar control, and therapeutic or molded shoes to help prevent amputation. The bill also requires coverage for diabetes self-management education and medical nutrition therapy, including group education and home visits when medically necessary, and directs plans to cover new or improved FDA-approved diabetes equipment and supplies as they become available.
Beginning January 1, 2026, the bill adds a cost-sharing limit for insulin administration and glucose monitoring supplies: covered persons may not be charged more than $25 for a 30-day supply, or per item if the item is intended to last longer than 30 days. The bill also bars annual deductibles for these supplies, except where applying the cap before a deductible is met would make a person ineligible for a health savings account under federal law; in that case, the cap applies only after the deductible is satisfied. A separate section applies the same cap and deductible rule to the state employee health plan when purchased or renewed by the director of administration.
The bill’s impact is to expand and standardize diabetes-related insurance benefits across major categories of regulated health coverage in Rhode Island, while also limiting out-of-pocket costs for insulin-related supplies. It amends multiple chapters of the General Laws governing insurers, hospital service corporations, medical service corporations, and HMOs, and adds a new provision for state employee health insurance benefits. The practical effect is to reduce cost barriers for people with diabetes and to ensure coverage keeps pace with FDA-approved diabetes technology.
The general sentiment reflected in the bill’s progress appears strongly favorable. The bill passed the Senate on March 20, 2025 by a unanimous 35-0 vote, and there is no recorded committee opposition or transcript-based controversy in the provided materials. The unanimous vote suggests broad bipartisan support for lowering diabetes treatment costs and improving access to necessary supplies.
The main point of potential contention is the interaction between the new $25 cap and federal health savings account rules. The bill explicitly preserves HSA eligibility by delaying application of the cap until after a deductible is met when necessary, which indicates lawmakers were attentive to tax-advantaged plan design concerns. Otherwise, the bill’s requirements are straightforward and consumer-protective, with the only notable policy choice being the scope of mandated coverage and the level of cost-sharing limits.
The bill amends Rhode Island General Laws chapters 27-18, 27-19, 27-20, and 27-41 to require diabetes-related coverage in most major health insurance products, and adds chapter 36-12-2.6 to extend similar protections to the state employee health plan. It establishes a $25 cost-sharing cap for insulin administration and glucose monitoring supplies, prohibits annual deductibles for those items except where needed to preserve HSA eligibility, and requires coverage of FDA-approved new or improved diabetes equipment and supplies when medically appropriate. These changes affect insurers, hospital service corporations, medical service corporations, HMOs, state employee health coverage, and insured individuals with diabetes.
The bill appears to have broad support and little visible opposition. It passed the Senate unanimously, 35-0, and the provided record contains no committee transcript indicating disagreement. The overall tone is pro-consumer and health-access oriented, focused on reducing out-of-pocket costs for diabetes care and ensuring coverage for essential supplies and education.
There is little evidence of substantive contention in the available materials. The only technical issue addressed in the bill itself is how the $25 cap interacts with federal HSA rules under 26 U.S.C. § 223; the bill preserves HSA eligibility by postponing the cap until after the deductible is met when necessary. Aside from that tax-compatibility carveout, the measure does not show recorded disagreement in committee or on the floor.